Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $12M (up 2966.4% year over year) with net income of −$47M.
Q3 2026 key financials · XBRL
- Revenue
- $12M
- +2966.4% YoY · +5.2% QoQ
- Net income
- −$47M
- −26.9% YoY · +7.1% QoQ
- Operating margin
- -481.5%
- EPS (diluted)
- −$0.81
- +16.5% YoY · +10.0% QoQ
Source: XBRL data from the Dianthus Therapeutics, Inc. /DE/ (DNTH) Q3 2026 10-Q on SEC EDGAR. USD.
Dianthus Therapeutics, Inc. /DE/ Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $1.2M vs $0.4M YoY, up $0.8M from reimbursable claseprubart trial costs
- Operating margin not meaningful, operating loss $58.5M vs $40.3M YoY
- R&D expenses $45.6M vs $32.5M, driven by claseprubart trials and DNTH212/DNTH312 discovery
- Operating cash flow used $128.2M through nine months, vs $82.1M YoY
- Cash, equivalents and investments $1.2B, funding expected into 2030; CAPTIVATE results projected by year-end 2027
Risk Factors
- No material changes to risk factors from the December 31, 2025 Form 10-K
- Carried-forward risk: unidentified risks could materially harm business, financial condition, results and growth prospects
- Market risk: adverse developments could reduce the market price of common stock
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dianthus Therapeutics, Inc. /DE/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.